Cardiovascular Center of the University of Lisbon (CCUL), Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, Lisbon 1649-028, Portugal; Centro Hospitalar Universitário Lisboa Central, Alameda Santo António dos Capuchos, 1169-050, Lisbon, Portugal.
Serviço de Medicina III, Hospital Pulido Valente, CHULN, Lisbon, Portugal.
Eur J Intern Med. 2021 Dec;94:45-55. doi: 10.1016/j.ejim.2021.10.014. Epub 2021 Nov 1.
In patients with venous thromboembolism (VTE), bleeding risk should be carefully assessed but none of the available risk scores is currently recommended. The aim of this study was to systematically evaluate the performance of bleeding scores in patients with VTE focusing on high-risk patients.
Longitudinal studies were searched in Medline and Cochrane Library, as well as reviews and references of retrieved articles. Studies were identified, data were extracted, and reporting quality was evaluated. We determined the sensitivity, specificity, positive likelihood ratio (LR+), and diagnostic odds ratio (DOR) of the 'high risk' category of each bleeding score. Random effects meta-analysis was performed in order to derive the central estimates and 95% confidence intervals (95% CI).
Twenty-one studies and ten bleeding scores fulfilled the inclusion criteria. VTE-BLEED showed the highest sensitivity but the second-lowest specificity (Se 76%; Sp 61%), followed by ACCP (Se 59%; Sp 57%). The remaining scores had high specificity (> 80%) but a low sensitivity (< 20%). HEMORRHAGES and Niewenhuis score showed the best performance regarding LR+ that was 2.67 and 5.91, respectively. Regarding DOR, the Niewenhuis score and VTE-BLEED were the best performers with 9.04; 95% CI 3.87-21.09 and 4.94 95% CI 2.66-9.09, respectively. In a cohort with patients predominantly treated with direct oral anticoagulants (DOACs), VTE-BLEED had the highest sensitivity (Se 77%; Sp 60%).
Overall, the majority of the risk scores showed a moderate ability to forecast major bleeding events, with the VTE-BLEED as the most sensitive in patients treated with DOACs.
在静脉血栓栓塞症(VTE)患者中,应仔细评估出血风险,但目前尚无推荐使用的风险评分。本研究旨在系统评估 VTE 患者出血评分的性能,重点关注高危患者。
在 Medline 和 Cochrane Library 中搜索纵向研究,以及检索到的文章的综述和参考文献。确定研究,提取数据,并评估报告质量。我们确定了每个出血评分的“高危”类别的敏感性、特异性、阳性似然比(LR+)和诊断比值比(DOR)。为了得出中心估计值和 95%置信区间(95%CI),采用随机效应荟萃分析。
21 项研究和 10 项出血评分符合纳入标准。VTE-BLEED 具有最高的敏感性,但特异性第二低(Se 76%;Sp 61%),其次是 ACCP(Se 59%;Sp 57%)。其余评分的特异性较高(>80%),但敏感性较低(<20%)。HEMORRHAGES 和 Niewenhuis 评分的 LR+分别为 2.67 和 5.91,表现最佳。关于 DOR,Niewenhuis 评分和 VTE-BLEED 的表现最好,分别为 9.04;95%CI 3.87-21.09 和 4.94 95%CI 2.66-9.09。在以直接口服抗凝剂(DOACs)治疗为主的患者队列中,VTE-BLEED 的敏感性最高(Se 77%;Sp 60%)。
总体而言,大多数风险评分显示出预测大出血事件的中等能力,在接受 DOACs 治疗的患者中,VTE-BLEED 的敏感性最高。